Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965688 · ClinicalTrials.gov registry record · Phase 2
Biology Guided Therapy for Breast Cancer for ER Positive
A Phase 2 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04965688 is a Phase 2 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 2 participants.
The verdict
NCT04965688, a Phase 2 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor. Right now, doctors do not have a good way of choosing between these treatments. Scientists we work with have come up with ways to use the biology of the tumor to try to predict which treatment is best. This study is being done to test if those predictions are right and to learn more about these tumors to design better treatments in the future.
Interventions
- DRUG Biopsy-Guided Therapy Selection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-08 |
| Est. Completion | 2024-03-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965688
The ClinicalTrials.gov registry entry for NCT04965688 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Biopsy-Guided Therapy Selection is the first listed.
NCT04965688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04965688 about?
NCT04965688 is a clinical study titled "Biology Guided Therapy for Breast Cancer for ER Positive". There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor. Right now, doctors do not have a good way of choosing between these treatments. Scientists we work with have ...
What is the current status of trial NCT04965688?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2021-08-08. Estimated completion is 2024-03-13.
What interventions are being tested in trial NCT04965688?
The interventions under investigation include: Biopsy-Guided Therapy Selection (DRUG).
Who is sponsoring clinical trial NCT04965688?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.